Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SETDB2 mitigates podocyte dysfunction in diabetic kidney disease through epigenetic silencing of SMAD3

ABSTRACT: Podocyte dysfunction represents both an early pathological hallmark and a key driver of proteinuria in diabetic kidney disease (DKD); however, the epigenetic mechanisms underlying this process remains poorly defined. Here, we identify the histone methyltransferase SETDB2 as a pivotal epigenetic suppressor of podocyte dysfunction and DKD progression. Glomerular SETDB2 expression is markedly reduced in both DKD patients and mouse models, showing an inverse correlation with disease severity. Podocyte-specific SETDB2 deficiency exacerbates podocytes dysfunction and accelerates DKD progression, whereas its overexpression exerts renal protective effects. Mechanistically, SETDB2 directly enhances H3K9 trimethylation at the Smad3 promoter, thereby repressing SMAD3 expression and activation, ultimately preserving podocyte function. Notably, we identify TCF21, a transcription factor downregulated in DKD, as a direct upstream regulator of Setdb2 expression via promoter binding and transcriptional activation. Collectively, these findings establish SETDB2 as a key regulator of podocyte integrity and a promising therapeutic target for DKD.

ORGANISM(S): Mus musculus

PROVIDER: GSE303915 | GEO | 2026/07/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SETDB2 mitigates podocyte dysfunction in diabetic kidney disease through epigenetic silencing of SMAD3 [MPC5-RNA-Seq]

Project description:Podocyte dysfunction represents both an early pathological hallmark and a key driver of proteinuria in diabetic kidney disease (DKD); however, the epigenetic mechanisms underlying this process remains poorly defined. Here, we identify the histone methyltransferase SETDB2 as a pivotal epigenetic suppressor of podocyte dysfunction and DKD progression. Glomerular SETDB2 expression is markedly reduced in both DKD patients and mouse models, showing an inverse correlation with disease severity. Podocyte-specific SETDB2 deficiency exacerbates podocytes dysfunction and accelerates DKD progression, whereas its overexpression exerts renal protective effects. Mechanistically, SETDB2 directly enhances H3K9 trimethylation at the Smad3 promoter, thereby repressing SMAD3 expression and activation, ultimately preserving podocyte function. Notably, we identify TCF21, a transcription factor downregulated in DKD, as a direct upstream regulator of Setdb2 expression via promoter binding and transcriptional activation. Collectively, these findings establish SETDB2 as a key regulator of podocyte integrity and a promising therapeutic target for DKD.

2026-07-31 | GSE303886 | GEO

SETDB2 mitigates podocyte dysfunction in diabetic kidney disease through epigenetic silencing of SMAD3 [Glomeruli RNA-Seq]

2026-07-31 | GSE303884 | GEO

SETDB2 mitigates podocyte dysfunction in diabetic kidney disease through epigenetic silencing of SMAD3 [Kidney RNA-Seq]

2026-07-31 | GSE303883 | GEO

SETDB2 mitigates podocyte dysfunction in diabetic kidney disease through epigenetic silencing of SMAD3 [Conditional knockout mice-Glomeruli-RNA-Seq]

2026-07-31 | GSE303885 | GEO

C-reactive protein promotes diabetic kidney disease via Smad3 mediated NLRP3 inflammasome activation

Project description:Diabetic kidney disease (DKD) is the leading cause of end-stage kidney diseases resulting enormous social-economic burden. Accumulated evidence has indicated that C-reactive protein (CRP) exacerbates DKD by enhancing renal inflammation and fibrosis through TGF-β/Smad3 signaling. NLRP3 inflammasome is the key sensor contributing to renal inflammation. However, whether CRP enhances inflammation in DKD via NLRP3 inflammasome related pathway remains unknown. In this study, we demonstrate that CRP promotes DKD via Smad3-mediated NLRP3 inflammasome activation as mice overexpressing human CRP gene exhibits accelerated renal inflammation in diabetic kidneys, which is associated with the activation of Smad3 and NLRP3 inflammasome. In contrast, blockade of CPR signaling with a neutralizing anti-CD32 antibody attenuates CRP-induced activation of Smad3 and NLRP3 in vitro. Importantly, genetic deletion or pharmacological inhibition of Smad3 also mitigates CRP-induced activation of NLRP3 in diabetic kidneys or in high glucose treated cells. Mechanistically, we reveal that Smad3 binds to the NLRP3 gene promoter which is enhanced by CRP. Taken together, we conclude that CRP induces renal inflammation in DKD via to the Smad3-NLRP3 inflammasome-dependent mechanism. Thus, targeting CRP or Smad3-NLRP3 pathways may be a new therapeutic potential for DKD.

2025-01-29 | GSE271870 | GEO

Tcf21 deletion from podocyte precursors as a model for congenital nephrotic syndrome

Project description:Here, we establish a mouse model of congenital nephrotic syndrome (NS) by genetic deletion of transcription factor 21 (Tcf21), a gene required for normal podocyte development, selectively from early podocyte precursors. Single cell transcriptomics of kidneys from these mice capture glomerular and tubulointerstitial changes that occur early in the course of NS and provide additional insights into: 1) the regulation of podocyte development and function by TCF21, 2) the effects of podocyte injury on other glomerular cells, and 3) the tubulointerstitial changes that occur in response to the glomerular dysfunction and associated massive proteinuria of podocytopathies.

2026-05-04 | GSE311499 | GEO

Oncogenic roles of SETDB2 histone methyltransferase in gastric cancer

Project description:Histone H3 lysine 9 tri-methyltransferases (H3K9me3) are related to transcriptional gene silencing. Although SETDB2 has H3K9me3 activity, it is unknown whether SETDB2 is linking to carcinogenesis. Here, we studied alterations and functions of SETDB2 in gastric cancers (GCs). In human clinical samples, overexpression of SETDB2 protein was observed in 30 of 72 (41.7%) primary GC tissues compared with their normal counterparts, and significantly associated with poor prognosis of the patients (P<0.05). SETDB2 protein was significantly detected in late stage of GCs. Moreover, SETDB2 protein was strongly expressed in four (30.8%) of 13 GC cell lines, and knockdown of SETDB2 led to decrease the cell proliferation, migration and invasion. According to the microarray analysis on a GC cell line after knockdown of SETDB2, the expression of WWOX and CADM1 tumor suppressor genes was significantly up-regulated. ChIP analysis showed that the H3K9me3 levels at the promoter regions of WWOX and CADM1 genes were closely regulated by the SETDB2 in GC cells. We also found that SETDB2 bound to the promoter regions after SETDB2 overexpression. Our data suggest that SETDB2 is associated with transcriptional repression of WWOX and CADM1, through H3K9me3, and hence overexpression of SETDB2 may contribute to gastric progression. Transfection of SETDB2 siRNA into MKN74 cells were performed by electroporation. After 48hrs, cells were harvested. Total RNA was used for cDNA microarray.

2016-02-21 | E-GEOD-76135 | biostudies-arrayexpress

NSD2 Drives Podocyte Injury in Diabetic Kidney Disease via Epigenetic Regulation of Hippo Signaling

Project description:Podocyte lipid accumulation has emerged as an important driver during the progression of diabetic kidney disease (DKD), yet the underlying mechanisms remain not fully clarified. Here, we identified the histone methyltransferase NSD2 as a key epigenetic regulator of podocyte lipid accumulation and injury in DKD. NSD2 expression is markedly increased in podocytes from both DKD patients and mouse models, and its levels shows a positive correlation with disease severity. Genetic deletion of Nsd2 in podocytes, as well as pharmacological inhibition of its methyltransferase activity, substantially reduced podocyte injury and proteinuria in mouse models. In contrast, transgenic Nsd2 overexpression in podocytes aggravated these pathological alterations. Mechanistically, elevated NSD2 in DKD enhances H3K36me2 deposition at the Ajuba promoter, resulting in its transcriptional upregulation and subsequent suppression of Hippo signaling. This epigenetic change promotes lipid accumulation in podocytes, leading to cytoskeletal disturbances and increased apoptosis. Collectively, our findings reinforce lipid accumulation as a central contributor to DKD progression and indicate that NSD2, as a pivotal epigenetic regulator in this process, could represent a reasonable therapeutic target for DKD.

2026-02-01 | GSE311115 | GEO

NSD2 Drives Podocyte Injury in Diabetic Kidney Disease via Epigenetic Regulation of Hippo Signaling [Cut & Run]

2026-02-01 | GSE311118 | GEO

NSD2 Drives Podocyte Injury in Diabetic Kidney Disease via Epigenetic Regulation of Hippo Signaling [RNA-Seq]

2026-02-01 | GSE313713 | GEO